Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine in Hib-primed toddlers

Booy R., Richmond P., Nolan T., McVernon J., Marshall H., Nissen M., Reynolds G., Ziegler J.B., Stoney T., Heron L., Lambert S., Mesaros N., Peddiraju K. and Miller J.M. (2013) Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine in Hib-primed toddlers. Pediatric Infectious Disease Journal, 32 2: 169-174. doi:10.1097/INF.0b013e3182787bff

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Booy R.
Richmond P.
Nolan T.
McVernon J.
Marshall H.
Nissen M.
Reynolds G.
Ziegler J.B.
Stoney T.
Heron L.
Lambert S.
Mesaros N.
Peddiraju K.
Miller J.M.
Title Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine in Hib-primed toddlers
Journal name Pediatric Infectious Disease Journal   Check publisher's open access policy
ISSN 0891-3668
Publication date 2013
Sub-type Article (original research)
DOI 10.1097/INF.0b013e3182787bff
Open Access Status
Volume 32
Issue 2
Start page 169
End page 174
Total pages 6
Place of publication Philadelphia, PA, U.S.A.
Publisher Lippincott Williams & Wilkins
Collection year 2014
Language eng
Subject 2735 Pediatrics, Perinatology, and Child Health
2725 Infectious Diseases
2726 Microbiology (medical)
Abstract BACKGROUND: Persistence of seroprotective bactericidal antibody titers is important for long-term protection against meningococcal serogroup C disease in young children. Antibody persistence values were determined in children up to 3 years after vaccination with a single dose of the combined Haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C (MenC)-tetanus toxoid (TT) conjugate vaccine (Hib-MenC-TT; www.ClinicalTrials.gov: NCT00326118). METHODS: The children had been randomized at ages 12-18 months to receive either 1 dose of Hib-MenC-TT (Hib-MenC group) or separately administered Hib-TT conjugate vaccine and MenC-CRM197 (MCC) vaccine (Hib plus MCC group). All children had been primed in infancy with a Hib vaccine. Antibodies against MenC were measured by a serum bactericidal assay using rabbit complement (rSBA-MenC) and antibodies against Hib polyribosylribitol phosphate were assessed by enzyme-linked immunosorbent assay. RESULTS: The rSBA-MenC titers ≥1:8 were demonstrated 3 years after vaccination in 64.2% and 53.2% of participants in the Hib-MenC group and in the Hib plus MCC group, respectively. Antipolyribosylribitol phosphate concentrations ≥0.15 μg/mL persisted in >98% of participants in both groups. The rSBA-MenC geometric mean titers and antipolyribosylribitol phosphate geometric mean concentrations remained higher 3 years after vaccination than before vaccination. No serious adverse events assessed by the investigator as being related to vaccination were reported. CONCLUSION: In this antibody persistence study of Hib-primed but MenC-naïve toddlers who received a single dose of Hib-MenC-TT, protective antibody levels against Hib and MenC were maintained in the majority of children 3 years after vaccination. Copyright
Keyword antibody persistence
Haemophilus influenzae type b
Neisseria meningitidis serogroup C
toddlers
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 7 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 12 Feb 2014, 14:08:55 EST by Matthew Lamb on behalf of School of Medicine